TABLE 2.
Characteristics of the included studies.
| Study (years) | State | Species (Sex, Wight, n = Treatment/Control Group) | Methods of i/R | I/R Duration | Anesthetics | Treatment Group | Control group | Outcome Index | Staining Method | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Type | Dosage | Approach (Time) | |||||||||
| Bai YJ 2019 | China | Sprague-Dawley rats (male, 220–250 g, n = 18/6) | in vivo | 30 min/2 h | pentobarbital sodium | biochanin A | 12.5, 25, 50 mg/kg/d | intragastric administration (before I/R) | I/R | IFS | TTC staining |
| Cui YC 2017 | China | Sprague-Dawley rats (male, 230–270 g, n = 18/6) | in vivo | 30 min/1.5 h | urethane | kaempferol | 2.5, 5 or 7.5 mg/kg/h | intravenous infusion (start from 30 min before ischemia until the end of reperfusion) | I/R + NS | IFS, cTnI, HR | Evan’s blue/TTC staining |
| Gu M 2016 | China | Sprague-Dawley rats (male, 250–300 g, n = 18/6) | in vivo | 30 min/1 h | pentobarbital sodium | genistin | 20, 40, 60 mg/kg | intragastric administration (before I/R) | I/R | IFS, CK | TTC staining |
| Jiang LJ 2021 (1) | China | C57BL/6J mice (male, n = 4/4) | in vivo | 30 min/24 h | pentobarbital sodium | ginsenoside Rb1 | 50 mg/kg | i.p. (before I/R) | I/R | IFS | TTC staining |
| Jiang LJ 2021 (2) | China | C57BL/6J mice (male, n = 4/4) | in vivo | 30 min/24 h | pentobarbital sodium | ginsenoside Rb1 | 50 mg/kg | i.v. (at the onset of reperfusion) | I/R | IFS | TTC staining |
| Jiang LJ 2021 (3) | China | C57BL/6J mice (male, n = 4/4) | in vivo | 30 min/24 h | pentobarbital sodium | ginsenoside Rb1 | 50 mg/kg | i.p. (after reperfusion) | I/R | IFS | TTC staining |
| Li CY 2020 | China | Sprague-Dawley rats (male, 230–250 g, n = 18/6) | in vivo | 45min/2 h | chloral hydrate | ginsenoside Rb1 | 20、40、80 mg/kg | i.p. (before IR) | I/R | IFS | TTC staining |
| Li GH 2016 | China | Sprague-Dawley rats (male, 220–250 g, n = 6/6) | in vivo | 30 min/2 h | pentobarbital sodium | ginsenoside Rb1 | 40 mg/kg | intravenous injection (before reperfusion) | I/R + DMSO | IFS, HR | TTC staining |
| Li L 2018 | China | Sprague-Dawley rats (male, 240–260 g, n = 6/6) | in vivo | 30 min/1.5 h | pentobarbital sodium | ginsenoside Rg1 | 5 mg/kg/h | intravenous infusion (start from 30 min before ischemia until the end of reperfusion) | I/R + NS | IFS, cTnI | Evan’s blue/TTC staining |
| Li Q 2016 | China | Sprague-Dawley rats (male, 210–250 g, n = 26/13) | in vivo | 30 min/2 h | pentobarbital sodium | tanshinone IIA | 10 mg/kg, 20 mg/kg | intravenous injection (before I/R) | I/R | IFS | Evan’s blue/TTC staining |
| Ling YN 2016 | China | C57BL/6J mice (male, 20–25 g, n = 4/4) | in vivo | 30 min/2 h | xylazine and ketamine | polydatin | 7.5 mg/kg | i.p. (after reperfusion) | I/R + NS | IFS, LVEF, LVFS | Evan’s blue/TTC staining |
| Wang D 2017 | China | Sprague-Dawley rats (male, 250–300g, n = 18/6) | in vivo | 30 min/2 h | pentobarbital sodium | kaempferide | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg | unclear (before I/R) | I/R | IFS, CK, LVEF, LVFS | TTC staining |
| Wang DS 2020 | China | Sprague-Dawley rats (male, 250–280 g, n = 20/10) | in vivo | 60 min/24 h | isoflurane | formononetin | 10 mg/kg, 30 mg/kg | intraperitoneal injection (when reperfusion started) | I/R + vehicle | IFS, cTnI, LVEF, LVFS | Evan’s blue/TTC staining |
| Wang ZK 2020 | China | C57BL/6J mice (male, 20–25 g, n = 6/6) | in vivo | 30 min/24 h | pentobarbital sodium | puerarin | 100 mg/kg | intraperitoneal injection (before reperfusion) | I/R | IFS, LVEF, LVFS | Evan’s blue/TTC staining |
| Wu B 2018 (1) | China | Sprague-Dawley rats (male, 220–250 g, n = 8/8) | in vivo | 30 min/24 h | isoflurane | Icariin | 60 mg/kg | intragastric administration (after I/R) | I/R + DMSO/PBS | IFS, LVEF, LVFS | Evan’s blue/TTC staining |
| Wu B 2018 (2) | China | C57BL/6J mice (male, 20–25 g, n = 8/8) | ex vivo | 40 min/1 h | pentobarbital sodium | Icariin | 10 μmol/L | Langendorff perfusion (during reperfusion) | I/R | IFS, HR | TTC staining |
| Lin Q 2018 | China | Sprague-Dawley rats (male, 200–250 g, n = 9/3) | in vivo | 30 min/24 h | pentobarbital sodium | rutin | 80 mg/kg, 40 mg/kg, 20 mg/kg | i.p. (before I/R) | I/R + NS containing 0.5% CMC-Na | IFS, cTnI, LVEF, LVFS | TTC staining |
| Liu XY 2016 | China | C57/BL6 mice (male, 20–22 g, n = 6/6) | in vivo | 30 min/24 h | isoflurane | quercetin | 250 mg/kg | intragastric administration (before I/R) | I/R + DMSO | IFS, LVEF, LVFS | Evan’s blue/TTC staining |
| Yang L 2016 | China | Sprague-Dawley rats (male, n = 10/10) | ex vivo | 30 min/1 h | chloral hydrate | resveratrol | 10 μmol/L | Langendorff perfusion (during reperfusion) | I/R | IFS | TTC staining |
| Kazemirad H 2020 | Iran | Wistar rats (male, 250–300 g, n = 10/10) | ex vivo | 30 min/2 h | thiopental sodium | resveratrol | 10 μmol/L | Langendorff perfusion (before I/R and during reperfusion) | I/R | IFS, cTnI, HR | TTC staining |
PE: phytoestrogen; LAD: left anterior descending; IFS: infarct size; TTC: tetrazolium chloride; HR: heart rate; CK: creatine kinase; cTnI: cardiac troponin I; NS: normal saline; i. p.: intraperitoneal injection; i. v, intravenous injection; DMSO: dimethyl sulfoxide; LVEF: left ventricular ejection fraction; LV, left ventricular ejection fraction; LVFS: left ventricular fractional shortening.: left ventricular fractional shortening.